PATENT CLAIM ANALYSIS

Application Number: 16369905
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "021500"]

Abstract:
A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

Claim (Index 15):
The method of  claim 1 , wherein the class I MHC molecule is HLA-A*02.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 2.53571
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16283540', '16283528', '16274491', '16100858', '15639058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8068282594176865
- 35 USC 102 Novelty (BERT): 0.5531979051944995
- Combined Prediction Score: 0.7814652239953678
- Mean Citation Score: 412.721
- Max Citation Score: 414.8405
- Similarity Product: 373.5388716409207

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test